Research Solutions

Proven Predictability

The applicability of patient-derived xenografts (PDX) in research settings is all encompassing. Champions TumorGraft® PDX models can be utilized in a variety of different study designs, including:

  • Screening
  • Efficacy
  • Tolerability
  • PK/PD
  • Simulated mouse clinical trials

It is the latter that is the most exciting – and potentially most rewarding. Through our close collaborative working relationships with major cancer centers worldwide, we are able to offer large cohorts — often more than fifty models — of low passage models that can be available in real time, complete with relevant standard of care response data and next-generation sequencing genomics.

A Cost Effective Way to Extend Your Budget

Studies with Champions TumorGraft PDX models are a highly cost-effective solution to help guide decision making for clinical development scenarios. In fact, they can be 90% less costly than pharmaceutical industry clinical trial costs.

Clinical studies can cost $100K – $200K per human patient, while the costs of a simulated clinical trial with Champions TumorGraft® PDX models are typically tenfold lower at $10k to $20k per PDX model. That means a single trial with PDX models that predicts positive results or prevents the initiation of one that is likely to fail can refinance ten or more translational studies. Consider the impact of a 10 fold increase in your research budget! Because Champions TumorGraft PDX models are an ideal platform for prediction of successful proof of concept studies, they can help procure funding for important new avenues of research.

Champions Oncology - Specializing in | Personalized Cancer Therapy | Translational Oncology Solutions | Oncology drug development | Oncology drug discovery | Translational oncology | Translation oncology research | Predictive oncology | Patient-derived xenograft model | Tumorgrafts | Alternative/new cancer treatment | Anticancer therapies | Personalized cancer treatment | Personalized cancer therapy | Personalized oncology